CD274 and non-small cell lung carcinoma: Navarixin was assessed for its efficacy and safety in combination with pembrolizumab, an anti-PD-1 monoclonal antibody, in a phase 2 clinical trial of three types of solid tumors: programmed death-ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC) (NCT03473925).